Recursion Pharmaceuticals (RXRX) Q4 2025 earnings review
Milestone Delivery and Cost Cuts Reverse the Cash Burn Trajectory
Recursion achieved a critical inflection point in Q4, delivering its first clinical proof-of-concept for its AI platform while simultaneously halting its runaway cash burn. Revenue spiked to $35.5M, driven by a $30M Roche milestone, but the real story is operational discipline. Net loss narrowed sequentially to $108.1M, the lowest in over a year, as post-Exscientia cost synergies took hold. Management's aggressive ATM utilization earlier in the year bolstered cash to $754M, extending the runway into early 2028. The TechBio narrative is finally transitioning from 'promises of AI' to 'clinical data and disciplined execution.'
🐂 Bull Case
REC-4881 (MEK1/2 inhibitor) showed a 43% median reduction in total polyp burden for FAP patients at 12 weeks, validating the Recursion OS's ability to identify novel phenotypic insights.
With $754M in cash and a commitment to keep 2026 operating cash expenses under $390M, the company has removed near-term financing overhangs in a tight macroeconomic environment.
🐻 Bear Case
The highly touted REC-4881 clinical proof rests on just 12 evaluable patients. This is far too small a sample to completely de-risk the asset or conclusively prove the platform's superiority.
The Q4 revenue surge was entirely dependent on a single $30M Roche milestone. Core recurring revenue does not exist yet, making quarterly financials highly volatile.
⚖️ Verdict: 🟢
Bullish. Recursion is doing exactly what a pre-commercial TechBio company must do to survive: proving its platform works in humans, monetizing early discoveries with Big Pharma, and radically defending its balance sheet.
Key Themes
First Clinical Proof-of-Concept for the AI OS
The Phase 2 TUPELO study for REC-4881 in Familial Adenomatous Polyposis (FAP) provided the first concrete clinical validation of Recursion's platform. The 4mg QD dose achieved a 43% median reduction in total polyp burden at 12 weeks, which was durably maintained at a 53% reduction after 12 weeks off therapy. This is a critical Reversing point in the narrative, shifting Recursion from a 'software discovery' company to a clinical-stage biotech with active biological validation.
The N=12 Reality Check Contradicts the AI 'Scale' Narrative
Despite management's heavy emphasis on 'massive scale' (processing 100+ billion cells, 50 petabytes of data), the actual clinical validation for REC-4881 relies on an efficacy-evaluable population of precisely 12 patients. While a 75% response rate in this group is encouraging, this tiny denominator contradicts the sweeping certainty of the 'AI solves biology' narrative. A Phase 2 failure in a larger cohort remains a high, unresolved risk.
Aggressive Cost Synergies Reshape the P&L
Following the Exscientia merger, management ruthlessly streamlined operations. G&A expenses dropped sequentially from $41.6M in 25Q3 to $33.7M in 25Q4. R&D expenses Decelerated from a peak of $129.6M in 25Q1 down to $95.9M in 25Q4. This disciplined integration is successfully Reversing the legacy trend of unchecked cash burn, proving management can execute on cost controls.
Big Pharma Partnerships Validate the Tech
Recursion's strategy of monetizing its platform early is paying off. In Q4, Roche accepted the second neuroscience Phenomap (microglial cells), triggering a $30M milestone. Post-quarter, Sanofi paid a $4M milestone for a novel oncology program. With >$500M in milestone payments achieved to date, these partnerships provide crucial non-dilutive capital and external validation of the 'Insight to Molecule' pipeline.
Lumpy Revenue Structure Complicates Modeling
Total revenue for 25Q4 was $35.5M, a massive jump from $5.2M in 25Q3. However, this is not recurring SaaS revenue; it is completely dependent on sporadic partner milestone acceptance. Management explicitly warns investors not to model quarterly revenue straight-line, making it difficult to assess true underlying commercial momentum.
Commoditizing Structural Biology via Boltz-2
In a major innovation move, Recursion partnered with MIT and NVIDIA to release Boltz-2, an open-source protein-ligand binding model that is ~1,000x faster than traditional physics-based calculations. By commoditizing basic structural prediction, Recursion aims to shift the industry's competitive moat toward massive, proprietary wet-lab data generation—a domain where they already possess 50 petabytes of multi-modal data.
Macro Pressures Prompted Heavy Dilution
To secure its balance sheet amid a challenging macroeconomic environment for biotech funding, Recursion fully utilized its At-the-Market (ATM) facility in late 2025. While this safely extended the cash runway to 2028, it resulted in a massive surge in the share count. Weighted-average shares outstanding spiked from 336M in 24Q4 to 526M in 25Q4, severely diluting existing shareholders.
Other KPIs
Accelerating significantly from $603.0M at the end of FY24. This growth was driven primarily by $387.5M in net proceeds from the ATM facility utilized in the second half of 2025, counterbalancing the $371.8M in net cash used in operating activities for the full year.
Accelerating 51% YoY from $314.4M in FY24. While Q4 showed a sharp sequential deceleration, the annual total was highly inflated by the Exscientia merger integration, $49.9M in record purchases from Tempus for patient-centric data, and $22.8M in acquired IPR&D.
Guidance
Decelerating. Management successfully brought 2025 operating cash expense to $399.2M (beating the <$450M target). The 2026 goal of <$390M excludes partnership inflows and transaction costs, highlighting strict ongoing cost discipline.
Stable/Extending. Driven by aggressive Q3/Q4 ATM utilization and lowered baseline burn rates. Crucially, this projection assumes 'no additional financing' and incorporates risk-adjusted milestone inflows.
Accelerating. Armed with 12-week and 25-week TUPELO data, the company plans to engage the FDA in 1H26 to define a registration pathway, aiming to move this asset toward pivotal trials.
Key Questions
Registration Pathway for REC-4881
With plans to engage the FDA in 1H26 regarding REC-4881 for FAP, what magnitude of polyp reduction will regulators require for accelerated vs. full approval, and how does the N=12 data support powering a pivotal study?
Visibility of 2026 Milestones
You achieved the 5th milestone with Sanofi in early 2026. Given the lumpy nature of revenue, what is the probability-weighted projection for milestone inflows that underpins the 'early 2028' cash runway?
Data Acquisition Costs
FY25 R&D was inflated by nearly $50M in Tempus data purchases. Are these massive third-party data acquisitions one-time structural investments for the OS, or should we expect similar recurring data costs in FY26 and beyond?